Axovant Sciences Ltd. (NYSE:AXON) has been assigned an average rating of “Buy” from the nine brokerages that are currently covering the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $25.80.

A number of research firms have weighed in on AXON. HC Wainwright reiterated a “buy” rating on shares of Axovant Sciences in a research note on Wednesday, August 17th. Zacks Investment Research upgraded Axovant Sciences from a “hold” rating to a “buy” rating and set a $17.00 target price on the stock in a research note on Monday, August 8th. Evercore ISI reiterated a “buy” rating and issued a $29.00 target price on shares of Axovant Sciences in a research note on Friday, September 23rd. Jefferies Group reiterated a “buy” rating and issued a $31.00 target price on shares of Axovant Sciences in a research note on Monday, September 26th. Finally, JMP Securities reiterated a “buy” rating on shares of Axovant Sciences in a research note on Tuesday, November 8th.

Several institutional investors have recently bought and sold shares of the company. Wells Fargo & Company MN increased its position in Axovant Sciences by 1.5% in the third quarter. Wells Fargo & Company MN now owns 8,130 shares of the company’s stock worth $113,000 after buying an additional 117 shares during the last quarter. California State Teachers Retirement System increased its stake in shares of Axovant Sciences by 0.8% in the third quarter. California State Teachers Retirement System now owns 51,649 shares of the company’s stock worth $723,000 after buying an additional 400 shares during the last quarter. Rhumbline Advisers increased its stake in shares of Axovant Sciences by 2.3% in the third quarter. Rhumbline Advisers now owns 21,971 shares of the company’s stock worth $308,000 after buying an additional 500 shares during the last quarter. Opus Point Partners Management LLC increased its stake in shares of Axovant Sciences by 10.9% in the third quarter. Opus Point Partners Management LLC now owns 14,844 shares of the company’s stock worth $208,000 after buying an additional 1,455 shares during the last quarter. Finally, TIAA CREF Investment Management LLC increased its stake in shares of Axovant Sciences by 2.6% in the third quarter. TIAA CREF Investment Management LLC now owns 77,911 shares of the company’s stock worth $1,091,000 after buying an additional 1,984 shares during the last quarter. 28.46% of the stock is currently owned by institutional investors and hedge funds.

Axovant Sciences (NYSE:AXON) opened at 13.45 on Friday. The stock has a 50 day moving average price of $13.08 and a 200 day moving average price of $13.79. The stock’s market cap is $1.33 billion. Axovant Sciences has a 52-week low of $8.86 and a 52-week high of $21.30.

TRADEMARK VIOLATION WARNING: This piece was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another domain, it was copied illegally and reposted in violation of US & international copyright and trademark law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2016/11/23/axovant-sciences-ltd-axon-receives-25-80-average-price-target-from-analysts.html.

About Axovant Sciences

Axovant Sciences Ltd., formerly Roivant Neurosciences Ltd., is a clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing therapeutics for the treatment of dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

5 Day Chart for NYSE:AXON

Receive News & Stock Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related stocks with our FREE daily email newsletter.